November 4, 2009 (Philadelphia, Pennsylvania) — Multidrug-resistant (MDR) Acinetobacter baumannii (ACBA) is a persistent threat to hospitalized patients, whether the infection is acquired in the ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

The current healthcare cleaning protocol may be inadequate to rid patient rooms of multidrug-resistant (MDR) Acinetobacter baumannii, according to a study in the December issue of the American Journal ...

Background. Minocycline is an "old-drug" with Food and Drug Administration approval for the treatment of infection due to Acinetobacter species. The purpose of this study is to describe an ...

Please provide your email address to receive an email when new articles are posted on . Multidrug-resistant (MDR) gram-negative bacteria continue to present an important threat to public health, and a ...

Second Phase 1 trial to emerge from Cubist's Labs in a week LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), announced today that it has begun dosing in the ...

The Bill and Melinda Gates Foundation has awarded Achaogen $10.5 million in grant funding and is making a $10 million investment in the South San Francisco-based firm to support the identification of ...

Healthy people can also carry the Acinetobacter bacteria on their skin, particularly if they work in a healthcare setting. It can survive for a long time on dry surfaces, making it difficult to ...

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced top-line results from a China phase I ...